

CITATION REPORT

List of articles citing

A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer

DOI: 10.1016/j.jval.2017.01.004
Value in Health, 2017, 20, 567-576.

Source: <https://exaly.com/paper-pdf/66571935/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
50	BRCA testing in women with ovarian cancer worth its cost. <i>PharmacoEconomics & Outcomes News</i> , 2017 , 774, 9-9	0.1	
49	Cost-effectiveness and comparative effectiveness of cancer risk management strategies in BRCA1/2 mutation carriers: a systematic review. <i>Genetics in Medicine</i> , 2018 , 20, 1145-1156	8.1	15
48	Real-world utilization of molecular diagnostic testing and matched drug therapies in the treatment of metastatic cancers. <i>Journal of Medical Economics</i> , 2018 , 21, 543-552	2.4	7
47	Cost-effectiveness analysis of germ-line BRCA testing in women with breast cancer and cascade testing in family members of mutation carriers. <i>Genetics in Medicine</i> , 2018 , 20, 985-994	8.1	44
46	LncRNA TP73-AS1 predicts poor prognosis and promotes cell proliferation in ovarian cancer via cell cycle and apoptosis regulation. <i>Molecular Medicine Reports</i> , 2018 , 18, 516-522	2.9	9
45	Identifying patients with a history of ovarian cancer for referral for genetic counselling: non-randomised comparison of two case-finding strategies in primary care. <i>British Journal of General Practice</i> , 2018 , 68, e750-e756	1.6	3
44	Pervasive genetic testing. <i>Lancet, The</i> , 2018 , 391, 2089-2091	4.0	3
43	Impact of Appointment Waiting Time on Attendance Rates at a Clinical Cancer Genetics Service. <i>Journal of Genetic Counseling</i> , 2018 , 27, 1473-1481	2.5	10
42	Personalising Treatment for High-Grade Serous Ovarian Carcinoma. <i>Clinical Oncology</i> , 2018 , 30, 515-524	2.8	10
41	BRCA germline mutation test for all woman with ovarian cancer?. <i>BMC Cancer</i> , 2019 , 19, 641	4.8	6
40	Impact of free cancer predisposition cascade genetic testing on uptake in Singapore. <i>Npj Genomic Medicine</i> , 2019 , 4, 22	6.2	15
39	Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer. <i>JAMA Network Open</i> , 2019 , 2, e194428	10.4	40
38	Health Technology Assessment Challenges in Oncology: 20 Years of Value in Health. <i>Value in Health</i> , 2019 , 22, 593-600	3.3	6
37	Targeted surgical prevention of epithelial ovarian cancer is cost effective and saves money in BRCA mutation carrying family members of women with epithelial ovarian cancer. A Canadian model. <i>Gynecologic Oncology</i> , 2019 , 153, 87-91	4.9	3
36	BRCA gene mutations: A population based review. <i>Gene Reports</i> , 2019 , 15, 100380	1.4	
35	Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion. <i>Journal of Clinical Oncology</i> , 2019 , 37, 153-164	2.2	73
34	Cost-utility analysis of germline BRCA1/2 testing in women with high-grade epithelial ovarian cancer in Spain. <i>Clinical and Translational Oncology</i> , 2019 , 21, 1076-1084	3.6	6

33	Foundations and Application of Precision Medicine. 2019 , 21-45		
32	Prevalence of and Mutations in Patients with Primary Ovarian Cancer - Does the German Checklist for Detecting the Risk of Hereditary Breast and Ovarian Cancer Adequately Depict the Need for Consultation?. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020 , 80, 932-940	2	4
31	Predictive Testing for Tumor Predisposition Syndromes in Pediatric Relatives: An Asian Experience. <i>Frontiers in Pediatrics</i> , 2020 , 8, 568528	3-4	
30	Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States. <i>JAMA Network Open</i> , 2020 , 3, e2022874	10.4	11
29	Canadian cost-effectiveness model of BRCA-driven surgical prevention of breast/ovarian cancers compared to treatment if cancer develops. <i>International Journal of Technology Assessment in Health Care</i> , 2020 , 36, 104-112	1.8	4
28	Recommendations for Advancing the Diagnosis and Management of Hereditary Breast and Ovarian Cancer in Brazil. <i>JCO Global Oncology</i> , 2020 , 6, 439-452	3-7	9
27	Promises and perils of using genetic tests to predict risk of disease. <i>BMJ, The</i> , 2020 , 368, m14	5-9	5
26	Genetic testing for epithelial ovarian cancer. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2020 , 65, 125-138	4-6	7
25	The New Genomics Era: Integration of genomics into mainstream oncology and implications for psycho-oncological care. <i>Psycho-Oncology</i> , 2020 , 29, 453-460	3-9	2
24	Analysis of risk communication teaching in psychosocial and other medical departments. <i>Medical Education Online</i> , 2020 , 25, 1746014	4-4	3
23	Investigation into the origins of an ancient BRCA1 founder mutation identified among Chinese families in Singapore. <i>International Journal of Cancer</i> , 2021 , 148, 637-645	7-5	3
22	Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome. <i>JAMA Oncology</i> , 2021 , 7, 230-237	13-4	53
21	A systematic review and meta-analysis of telephone vs in-person genetic counseling in BRCA1/BRCA2 genetic testing. <i>Journal of Genetic Counseling</i> , 2021 , 30, 563-573	2-5	8
20	Implementing Systematic Genetic Counseling and Multigene Germline Testing for Individuals With Pancreatic Cancer. <i>JCO Oncology Practice</i> , 2021 , 17, e236-e247	2-3	4
19	Cost-Effectiveness of Targeted Genetic Testing for Breast and Ovarian Cancer: A Systematic Review. <i>Value in Health</i> , 2021 , 24, 303-312	3-3	4
18	Cost-effectiveness of olaparib maintenance therapy when used with and without restriction by mutation status for platinum-sensitive relapsed ovarian cancer. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021 , 21, 441-448	2-2	1
17	Cascade Genetic Testing for Hereditary Cancer Risk: An Underutilized Tool for Cancer Prevention.. <i>JCO Precision Oncology</i> , 2021 , 5, 1387-1396	3-6	2
16	Cost effectiveness of breast cancer screening and prevention: a systematic review with a focus on risk-adapted strategies. <i>European Journal of Health Economics</i> , 2021 , 22, 1311-1344	3-6	1

15	A Cost Decision Model Supporting Treatment Strategy Selection in BRCA1/2 Mutation Carriers in Breast Cancer. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	1
14	Data on Utility in Cost-Utility Analyses of Genetic Screen-and-Treat Strategies for Breast and Ovarian Cancer. <i>Cancers</i> , 2021 , 13,	6.6	0
13	A Systematic Review of the Methodological Quality of Economic Evaluations in Genetic Screening and Testing for Monogenic Disorders.		
12	A cost-minimization analysis of a preventive testing strategy for relatives of patients with BRCA mutated ovarian cancer. <i>Global & Regional Health Technology Assessment</i> , 2020 , 7, 1-8	0.2	
11	Considerations on the identification and management of metastatic prostate cancer patients with DNA repair gene alterations in the Canadian context. <i>Canadian Urological Association Journal</i> , 2021 ,	1.2	
10	Decision thresholds with genetic testing. <i>European Journal of Health Economics</i> , 2021 , 1	3.6	1
9	Mainstreaming Genetic Testing for Adult Patients With Autosomal Dominant Polycystic Kidney Disease. <i>Canadian Journal of Kidney Health and Disease</i> , 2021 , 8, 20543581211055001	2.3	0
8	A systematic review of the methodological quality of economic evaluations in genetic screening and testing for monogenic disorders.. <i>Genetics in Medicine</i> , 2021 ,	8.1	0
7	Uptake Rates of Risk-Reducing Surgeries for Women at Increased Risk of Hereditary Breast and Ovarian Cancer Applied to Cost-Effectiveness Analyses: A Scoping Systematic Review.. <i>Cancers</i> , 2022 , 14,	6.6	2
6	Mainstream germline genetic testing for patients with epithelial ovarian cancer leads to higher testing rates and a reduction in genetics-related healthcare costs from a healthcare payer perspective. 2022 ,		
5	Cost-Effectiveness Analysis of Germline and Somatic BRCA Testing in Patients With Advanced Ovarian Cancer. 2023 , 43, 73-81		1
4	Genetic testing in ovarian cancer. 2022 , 16, 195-199		0
3	A review of the cost-effectiveness of genetic testing for germline variants in familial cancer. 2023 , 26, 19-33		1
2	Adherence to NCCN Genetic Testing Guidelines in Pancreatic Cancer and Impact on Treatment.		0
1	Chemotherapy-related agranulocytosis as a predictive factor for germline BRCA1 pathogenic variants in breast cancer patients: a retrospective cohort study. 2023 , 153, 40055		0